Limited Time Offer$99 GLP-1 Injections: While Supplies Last
Special PromoSave up to $100 on your first order · Flat $1,399/mo across all doses
Claim $100 Off
Authentic Eli Lilly Pen · Save up to $100 1st Order

Mounjaro®
from $1,399/mo.

FDA-approved once-weekly dual GIP and GLP-1 receptor agonist injection for type 2 diabetes glycemic control. Demonstrated superior HbA1c and weight reduction over semaglutide in SURPASS-2 trials. Flat rate across all doses.

Claim $100 Off First Order Discount auto-applied at checkout · FSA & HSA eligible · Free cold shipping
-2.30%
HbA1c Reduction (15mg)
-11.2 kg
Mean Weight Loss (15mg)
$1,399
Flat Monthly (All Doses)
46.0%
Reached Normoglycemia
Verified Clinical Drug Monograph
🔗#extractive-answer

What is Mounjaro and how does dual incretin receptor agonism improve glycemic control?

Mounjaro® (tirzepatide) is an FDA-approved weekly dual GIP and GLP-1 receptor agonist that reduced HbA1c by up to 2.30% and body weight by 11.2 kg in SURPASS-2, demonstrating superior glycemic and weight reductions compared to semaglutide 1.0 mg. Tirzepatide acts as a biased dual incretin agonist, engaging both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors on pancreatic beta cells to enhance first- and second-phase insulin secretion in a strictly glucose-dependent manner. GIP receptor activation further enhances glucagon secretion during hypoglycemia while suppressing it during hyperglycemia. Centrally and peripherally, dual incretin targeting delays gastric emptying and suppresses hypothalamic appetite signaling, producing unprecedented glycemic normalization (normoglycemia HbA1c <5.7% reached by 46% of patients in SURPASS-2).

SURPASS-2 HbA1c Reduction-2.30% at 15mg vs -1.86% for semaglutide (p<0.001)
Mean Weight Reduction-11.2 kg (-24.7 lbs) at 15mg vs -5.7 kg for semaglutide
Normoglycemia Rate46% achieved HbA1c < 5.7% at 15mg dose
Telehealth FX Pricing$1,399/mo flat (Save $100 on 1st order)
⚖️ Statutory Authority:FDA NDA 215866 Prescribing Information & Controlled Substances Act (Non-Controlled Rx)
📋 Clinical Standard:American Diabetes Association (ADA) Standards of Medical Care in Diabetes

Clinical Evidence: The SURPASS Trial Program

Mounjaro was evaluated across the SURPASS clinical development program, encompassing more than 19,000 patients across 10 global phase 3 clinical trials. The pivotal head-to-head study, SURPASS-2 (Frías et al., New England Journal of Medicine2021; 385:503-515, DOI: 10.1056/NEJMoa2107519), evaluated 1,879 adults with type 2 diabetes inadequately controlled on metformin (≥ 1,500 mg/day) randomized to tirzepatide (5, 10, or 15 mg) or semaglutide 1.0 mg once weekly for 40 weeks:

Treatment ArmCohort ($n$)Mean HbA1c ReductionMean Weight ChangeHbA1c < 5.7% Rate
Tirzepatide 5 mg470-2.01% (difference vs semag -0.15%)-7.6 kg (-16.8 lbs)27% of patients
Tirzepatide 10 mg469-2.24% (difference vs semag -0.39%)-9.3 kg (-20.5 lbs)40% of patients
Tirzepatide 15 mg470-2.30% (difference vs semag -0.45%)-11.2 kg (-24.7 lbs)46% of patients
Semaglutide 1.0 mg469-1.86% (reference active comparator)-5.7 kg (-12.6 lbs)19% of patients

Mounjaro Stepwise Titration Schedule

Mounjaro is administered once weekly at any time of day, with or without food. The dose escalation protocol minimizes gastrointestinal adverse effects while titrating to individual therapeutic glycemic goals:

StepTimingWeekly DoseClinical Directive
InitiationWeeks 1–42.5 mg weeklyStarting dose for treatment initiation; not effective for glycemic control alone.
Dose Tier 1Weeks 5–85.0 mg weeklyInitial glycemic maintenance dose; significant HbA1c drop.
Dose Tier 2Weeks 9–127.5 mg weeklyOptional intermediate escalation step if A1C remains elevated.
Dose Tier 3Weeks 13–1610.0 mg weeklyAdvanced therapeutic maintenance tier.
Dose Tier 4Weeks 17–2012.5 mg weeklyHigh-potency glycemic control tier.
Maximum DoseWeek 21+15.0 mg weeklyMaximum approved maintenance dose for intensive glycemic management.

Transform Your Glycemic Health with Mounjaro

Flat $1,399/mo rate across all six doses. Save up to $100 on your first month order. Comprehensive doctor oversight and free cold-chain express shipping.

See If You Qualify

FDA Safety Profile & Boxed Warning

Mounjaro carries an FDA Boxed Warning for Thyroid C-Cell Tumors. In rodent carcinogenicity studies, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.

BOXED WARNING & PRECAUTIONS

  • Contraindicated in patients with personal or family history of Medullary Thyroid Carcinoma (MTC).
  • Contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Contraindicated in patients with known serious hypersensitivity to tirzepatide.
  • Not indicated for use in type 1 diabetes mellitus or for treating diabetic ketoacidosis.

In SURPASS-2, the most frequent adverse events were gastrointestinal: nausea (17.4%–22.1%), diarrhea (13.3%–13.8%), vomiting (5.7%–9.8%), and constipation (5.8%–6.4%). Treatment discontinuation due to adverse events was 6.0% (5mg), 8.5% (10mg), and 8.5% (15mg) vs 4.1% for semaglutide 1.0 mg.

How the Telehealth FX Mounjaro Program Works

1

Complete Metabolic Intake

Answer questions regarding your diabetes diagnosis, current HbA1c levels, renal health, and concomitant medications.

2

Board-Certified MD Evaluation

A licensed physician reviews your medical history, verifies your clinical indication, and creates your individualized titration protocol.

3

Express Cold-Chain Delivery

Your authentic Eli Lilly Mounjaro single-dose pens ship in insulated, temperature-controlled packaging with 2-day delivery.

4

Continuous Glycemic Monitoring

Ongoing physician consultations and regular A1C tracking ensure your blood sugar reaches optimal targets with minimal side effects.

Frequently Asked Questions

What is Mounjaro and what is its primary FDA indication?

Mounjaro® (tirzepatide) is an FDA-approved prescription medication indicated as an adjunct to diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes mellitus. It is the first once-weekly dual GIP and GLP-1 receptor agonist approved in the United States.

How much does Mounjaro cost through Telehealth FX?

Through Telehealth FX, authentic Mounjaro is available at a flat rate of $1,399 per month across all dosage strengths (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg). First-time orders receive an automatic discount saving up to $100 at checkout ($1,299 for your first month). The fee includes your licensed physician evaluation, titration oversight, and temperature-controlled 2-day cold shipping.

How did Mounjaro compare to Ozempic (semaglutide) in the SURPASS-2 trial?

In the SURPASS-2 head-to-head trial (NEJM 2021, n=1,879), tirzepatide 15 mg proved statistically superior to semaglutide 1.0 mg in both HbA1c reduction (-2.30% vs -1.86%, p<0.001) and mean body weight reduction (-11.2 kg vs -5.7 kg, p<0.001). Up to 46% of patients on tirzepatide reached normoglycemia (HbA1c < 5.7%) compared to 19% on semaglutide.

What is the recommended Mounjaro titration schedule?

Mounjaro begins at 2.5 mg injected subcutaneously once weekly for 4 weeks to establish tolerability. At week 5, the dose increases to 5.0 mg weekly. If additional glycemic control is required, doses can be increased in 2.5 mg increments after at least 4 weeks on the current dose, through 7.5 mg, 10.0 mg, 12.5 mg, up to a maximum of 15.0 mg once weekly.

Can Mounjaro be used in patients with type 1 diabetes?

No. Mounjaro is not indicated for and should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it relies on stimulating endogenous pancreatic insulin production.

Can I pay for Mounjaro using HSA or FSA accounts?

Yes. Mounjaro is an FDA-approved clinical prescription medicine for type 2 diabetes. All medication and physician fees qualify as medical expenses under IRS Section 213(d) and can be paid directly with an HSA/FSA debit card.

VERIFIED PATIENT EXPERIENCES

Real Patient Reviews & Clinical Outcomes

4.8 out of 5· Based on 158 verified Mounjaro patient evaluations
✓ Verified Patient

"SURPASS-2 data convinced me to choose Mounjaro over semaglutide. A1C dropped from 8.1% to 5.4% and lost 31 lbs. Telehealth FX physician care is top-tier."

Richard G.Mar 29, 2026
✓ Verified Patient

"Fast medical assessment, same-day approval, and prompt arrival. The dual incretin mechanism provided immediate metabolic improvements."

Chloe T.Apr 18, 2026

Start Your Mounjaro Program Today

$1,399/mo flat rate across all doses. Save up to $100 on your first month order. Board-certified physician oversight. Free cold-chain express delivery.

Claim $100 Off First Order

Disclaimer: Mounjaro® is a registered trademark of Eli Lilly and Company. Telehealth FX is an independent telehealth management platform connecting patients with board-certified physicians and licensed pharmacies. Telehealth FX is not sponsored by, endorsed by, or affiliated with Eli Lilly and Company. Prescription requires clinical evaluation and approval by a licensed medical provider.